Li Sidan, Wu Runhui, Wang Bin, Fu Lingling, Zhu Guanghua, Zhou Xuan, Ma Jie, Zhang Liqiang, Qin Maoquan
Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics, Ministry of Education; Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.
J Pediatr Hematol Oncol. 2019 Jan;41(1):38-41. doi: 10.1097/MPH.0000000000001263.
The delay in platelet recovery after hematopoietic stem cell transplantation (HSCT) is closely related to the overall survival rate of transplanted children. The use of platelet-producing agents such as eltrombopag and romiplostim has made great progress in treating diseases such as immune thrombocytopenia and aplastic anemia. However, the use of such drugs in patients with thrombocytopenia after transplantation, especially in children, is rare. This study aimed to report eltrombopag treatment for 3 children with primary platelet engraftment failure and secondary thrombocytopenia after allogeneic HSCT. Of these patients, 2 had platelets stabilized at ≥50×10/L after eltrombopag treatment and subsequent withdrawal of eltrombopag. All 3 patients showed no clear adverse reactions. The results indicated a wide application prospect of eltrombopag treatment in children with thrombocytopenia after allogeneic HSCT.
造血干细胞移植（HSCT）后血小板恢复延迟与移植儿童的总体生存率密切相关。使用艾曲泊帕和罗米司亭等血小板生成剂在治疗免疫性血小板减少症和再生障碍性贫血等疾病方面取得了很大进展。然而，此类药物在移植后血小板减少患者中，尤其是儿童中的应用较少。本研究旨在报告艾曲泊帕治疗3例异基因HSCT后原发性血小板植入失败和继发性血小板减少症患儿的情况。在这些患者中，2例在接受艾曲泊帕治疗并随后停用艾曲泊帕后血小板稳定在≥50×10⁹/L。所有3例患者均未出现明显不良反应。结果表明艾曲泊帕治疗在异基因HSCT后血小板减少症患儿中具有广阔的应用前景。
